In brief
An international modelling study published in Nature Medicine predicts that the number of new cervical cancer cases will climb 20.2 % and deaths will rise 39.3 % by 2050, despite the disease being largely preventable. The greatest increases are expected in sub‑Saharan Africa, where incidence and mortality could almost double. The study urges expanded access to HPV vaccination, screening and treatment to avert this projected rise.
In a modelling study released in early November, researchers warned that cervical cancer will become an even bigger global health problem by 2050, with new cases rising 20.2 percent and deaths rising 39.3 percent from 2024 levels.
The paper, published in Nature Medicine, was a joint effort by Australian and international investigators who analysed incidence, mortality and health‑loss data for 204 countries and territories from 1990 to 2023 and projected trends to 2050.
According to the study, 887,000 women were diagnosed with cervical cancer and 369,000 died from the disease in 2023. By 2050 the researchers expect yearly cases to climb to about 1.08 million and deaths to reach 522,000.
Sub‑Saharan Africa will carry the greatest burden of the increase. The model projects an 88.7 percent rise in new cases and a 95.4 percent rise in deaths in the region, with annual deaths reaching an estimated 206,000 by 2050.
Even in the most optimistic scenario, none of the seven world regions studied is projected to hit the World Health Organization’s cervical cancer elimination threshold of fewer than four cases per 100,000 women by 2050.
Roughly a quarter of the 2023 burden—new cases and deaths—occurred in low‑income countries, where the age‑standardised incidence rate was more than four times higher and mortality more than seven times higher than in high‑income countries, the authors noted.
"The condition is largely preventable,” one author said, adding that greater access to human papillomavirus (HPV) vaccination, screening and treatment is essential. The modelling shows that current trends, if left unchanged, would drive the disease burden upward.
HPV vaccination campaigns have varied worldwide. The study found disparities in uptake: many high‑income countries have reached high coverage rates, while many low‑income countries still have limited vaccine availability or offer it only to a small portion of eligible girls or young women.
Screening access also lags in regions where cervical cancer rates are highest. The authors highlighted that in sub‑Saharan Africa, a large share of women live in rural areas with few screening facilities, and even where screening exists, follow‑up treatment is often delayed or unavailable.
The paper’s authors urged policymakers to accelerate efforts to achieve the WHO target of 90 % HPV vaccine coverage by age 15 and 70 % screening coverage by ages 35–45 and 45–49 by 2030.
As the study was released, international bodies urged a global commitment to the World Health Organization’s cervical cancer elimination strategy, which calls for a comprehensive package of vaccination, screening and treatment. The modelling underscores how failure to deliver these interventions will translate into higher incidence and mortality, particularly in low‑resource settings.
At present, the evidence points to a dire need for increased investment in vaccination programs, screening outreach, and treatment infrastructure to reverse the projected trend. The precise pathways to achieve adequate coverage and equity remain an open question for health policy makers and researchers worldwide.
